NeuroDerm (NDRM) Misses Q2 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. TMUS
9. SPY
10. SBUX

Go back to NeuroDerm (NDRM) Misses Q2 EPS by 12c

NeuroDerm (NDRM) Commences Enrollment in ND0612L Phase 3 as Parkinson's Disease Treatment

August 25, 2016 7:20 AM EDT

NeuroDerm Ltd. (Nasdaq: NDRM) announced that it has initiated enrollment of Parkinson's disease (PD) patients in a Phase III efficacy trial (trial 007, named the "iNDiGO" trial) of ND0612L, the companys low-dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation.

iNDiGO is a 16-week, international, multicenter, randomized, double-blind, placebo controlled, parallel group study designed to compare the efficacy, safety and tolerability of continuous subcutaneous infusion of adjunct ND0612L therapy with oral standard-of-care and placebo in patients who suffer from motor fluctuations despite optimized standard-of-care... More